Dr. Benjamin L. Maughan, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 162
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license 49008 -
Hematology & Oncology Physician
TX license 49008 · UT license 8134434-1205 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
- Ut Health San Antonio Multispecialty & Research Ho San Antonio, TX
Medical groups
- University of Utah Adult Services (1,788 clinicians)
- University of Texas Health Science Center at San Antonio (1,297 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 162
- Services billed
- 662
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 361 | 136 |
| Established patient office or other outpatient visit, 30-39 minutes | 101 | 76 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 445 |
| Eplerenone Other prescribers in San Antonio, TX | 171 |
| Prednisone Other prescribers in San Antonio, TX | 138 |
| Potassium Chloride Other prescribers in San Antonio, TX | 32 |
| Levothyroxine Sodium Other prescribers in San Antonio, TX | 28 |
| Amlodipine Besylate Other prescribers in San Antonio, TX | 28 |
| Xtandi (enzalutamide) | 25 |
| Ondansetron Hcl Other prescribers in San Antonio, TX | 25 |
| Orgovyx (relugolix) | 24 |
| Welireg (belzutifan) | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 31 payments worth $21,454 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $11,584 |
|---|---|
| Eisai Inc. | $4,974 |
| Pfizer Inc. | $2,346 |
| Eisai Co., LTD. | $2,205 |
| Exelixis Inc. | $197 |
| Aveo Pharmaceuticals, Inc. | $148 |
| Consulting Fee | $18,644 |
|---|---|
| Food and Beverage | $1,498 |
| Travel and Lodging | $1,312 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Consulting Fee Xofigo · Oncology | $7,210 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Consulting Fee Nubeqa · Oncology | $2,524 |
| Eisai Inc. Dec 3, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Eisai Co., LTD. Mar 14, 2025 | Consulting Fee Lenvima · Oncology | $2,205 |
| Eisai Inc. Mar 14, 2025 | Consulting Fee Lenvima · Oncology | $2,205 |
| Pfizer Inc. Mar 12, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $2,100 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $576 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 24, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $238 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $238 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 24, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $215 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Dec 3, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Consulting Fee Nubeqa · Oncology | $2,524 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Rosemont, IL · in-kind | $26.88 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Consulting Fee Xofigo · Oncology | $7,210 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $576 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $238 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 24, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $238 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 24, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $215 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 24, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Rosemont, IL · in-kind | $17.91 |
| Eisai Co., LTD. Mar 14, 2025 | Consulting Fee Lenvima · Oncology | $2,205 |
| Eisai Inc. Mar 14, 2025 | Consulting Fee Lenvima · Oncology | $2,205 |
| Pfizer Inc. Mar 12, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $2,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $1,166,030 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
Merck Sharp & Dohme LLC - A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma
Merck Sharp & Dohme LLC - An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 …
Merck Sharp & Dohme LLC - A Phase 2 Study of Radium-223 + Nivolumab in Men with Metastatic Castration Resistant Prostate Cancer
E.r. Squibb & Sons, L.l.c. - BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.